Global Initiative for Asthma
Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC
Diese Leitlinie umfasst 7 Empfehlungen und 739 Literaturangaben.
Inhalt auf Englisch
Zusammenfassung
The GINA 2019 update provides global evidence-based recommendations for the diagnosis, assessment, and management of asthma. A major update is the recommendation against short-acting beta2-agonist (SABA)-only treatment for adults and adolescents, instead recommending inhaled corticosteroid (ICS)-containing controllers to reduce the risk of severe exacerbations. The guideline also details stepwise management, management of severe asthma, pediatric asthma, and asthma-COPD overlap.
Asthma is a serious global health problem. GINA was established to disseminate information about the care of patients with asthma and to provide a mechanism to translate scientific evidence into improved asthma care globally.
Kernaussagen
SABA-only treatment is no longer recommended for the treatment of asthma in adults and adolescents.
All adults and adolescents with asthma should receive either symptom-driven or daily inhaled corticosteroid (ICS)-containing controller treatment to reduce the risk of severe exacerbations.
For mild asthma, preferred treatment is low dose ICS-formoterol taken as needed for symptom relief.
Tiotropium is approved as an add-on therapy for children ages 6 years and older.
Dupilumab (anti-IL4 receptor α) is recommended for patients ≥12 years with severe Type 2 asthma or OCS-dependent asthma.
Maintenance oral corticosteroids (OCS) are no longer a preferred treatment in Step 5 due to the high risk of adverse outcomes.
Difficult-to-treat asthma must be distinguished from severe asthma by checking adherence, inhaler technique, and managing comorbidities before stepping up to biologic therapies.
